These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22264790)

  • 1. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
    Van der Veldt AA; Lubberink M; Bahce I; Walraven M; de Boer MP; Greuter HN; Hendrikse NH; Eriksson J; Windhorst AD; Postmus PE; Verheul HM; Serné EH; Lammertsma AA; Smit EF
    Cancer Cell; 2012 Jan; 21(1):82-91. PubMed ID: 22264790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
    Reinmuth N; Heigener D; Reck M
    Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
    Görn M; Habermann CR; Anige M; Thöm I; Schuch G; Andritzky B; Brandl S; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C; Laack E
    Onkologie; 2008 Apr; 31(4):185-9. PubMed ID: 18418020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenesis drugs in lung cancer.
    Lee SM; Baas P; Wakelee H
    Respirology; 2010 Apr; 15(3):387-92. PubMed ID: 20337999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.
    van der Veldt AA; Lubberink M; Mathijssen RH; Loos WJ; Herder GJ; Greuter HN; Comans EF; Rutten HB; Eriksson J; Windhorst AD; Hendrikse NH; Postmus PE; Smit EF; Lammertsma AA
    Clin Cancer Res; 2013 Aug; 19(15):4163-73. PubMed ID: 23620410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
    Reinmuth N; Steins M; Kreuter M; Thomas M
    Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.